Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Russell W. Jenkins|Nature|2023Cited by 165
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng‐Ju Wu, Nabeel Bardeesy, Qin Xu et al.|Science|2024Cited by 87
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor SpheroidsYi Sun, Russell W. Jenkins|Cancer Immunology Research|2025Cited by 15